Cross-validation of a Shortened Battery for the Assessment of Dysexecutive Disorders in Alzheimer Disease
The frequency of executive disorders in mild-to-moderate Alzheimer disease (AD) has been demonstrated by the application of a comprehensive battery. The present study analyzed data from 2 recent multicenter studies based on the same executive battery. The objective was to derive a shortened
battery by using the GREFEX population as a training dataset and by cross-validating the results in the REFLEX population. A total of 102 AD patients of the GREFEX study (MMSE=23.2±2.9) and 72 patients of the REFLEX study (MMSE=20.8±3.5) were included. Tests were selected and
receiver operating characteristic curves were generated relative to the performance of 780 controls from the GREFEX study. Stepwise logistic regression identified 3 cognitive tests (Six Elements Task, categorical fluency and Trail Making Test B error) and behavioral disorders globally referred
as global hypoactivity (P=0.0001, all). This shortened battery was as accurate as the entire GREFEX battery in diagnosing dysexecutive disorders in both training group and the validation group. Bootstrap procedure confirmed the stability of AUC. A shortened battery based on 3 cognitive
tests and 3 behavioral domains provides a high diagnosis accuracy of executive disorders in mild-to-moderate AD.
No Reference information available - sign in for access.
No Citation information available - sign in for access.
No Supplementary Data.
No Article Media
mild cognitive impairment;
sensitivity and specificity
Document Type: Research Article
Departments of Neurology, Laboratory of Functional Neurosciences
Department of Neurology, Rouen University Hospital, Rouen
Geriatric Center, CMRR, Pitié-Salpêtrière University Hospital (AP-HP and UPMC)
Department of Neurology, CMRR, University Hospital of Grenoble, Grenoble
Department of Gerontology, Research Team EA4468, Broca Hospital
Department of Neurology, General Hospital of Cholet, Cholet
Biostatistics, University Hospital of Amiens, Amiens
Novartis Pharma SAS, Paris
Department of Neurology, University Hospital of Reims, Reims
Office of Neurology, Bergerac, France
April 1, 2016